Pharma
1 min read

Merck to supply up to 1 mln courses of COVID-19 pill to Canada

The government of Canada has secured access to 500,000 courses in 2022, with options for up to 500,000 more, pending Health Canada's approval, the company said.

Reuters

Published On Dec 4, 2021 at 12:01 PM IST

Merck & Co said on Friday it would supply the Canada with up to 1 million courses of molnupiravir, its experimental oral antiviral medicine for the treatment of COVID-19.

The government of Canada has secured access to 500,000 courses in 2022, with options for up to 500,000 more, pending Health Canada's approval, the company said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel)